| Followers | 144 |
| Posts | 28017 |
| Boards Moderated | 4 |
| Alias Born | 02/07/2004 |
Wednesday, April 16, 2025 11:49:17 AM
Methinks the intention of the PR was to arouse
awareness to some BP in order to form some
joint venture, coop, or any other arrangement
bearing upfront $$$ and further investment in
developing the coming stages.
Now let us see if any BP bites!
awareness to some BP in order to form some
joint venture, coop, or any other arrangement
bearing upfront $$$ and further investment in
developing the coming stages.
Now let us see if any BP bites!
Recent RDHL News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2026 09:00:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:13 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/04/2026 08:40:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 11:02:46 AM
- RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease • PR Newswire (US) • 04/30/2026 11:00:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/27/2026 12:18:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 12:04:19 PM
- RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights • PR Newswire (US) • 04/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 10:09:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/22/2026 12:02:19 PM
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 • PR Newswire (US) • 04/22/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:00:07 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 02:00:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:01:02 PM
- Joint U.S. Commercialization of RedHill's Talicia® Commences • PR Newswire (US) • 02/25/2026 12:00:00 PM
